Robert Motzer
Jack and Dorothy Byrne Chair in Clinical Oncology · New York Presbyterian Hospital
Credentials: · · · · ·
History
Research
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2015 · First of 28 authors · 4,745 citations
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
New England Journal of Medicine · 2007 · First of 14 authors · Corresponding · 4,727 citations
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2018 · First of 33 authors · 3,758 citations
- GE
120 papers
115 papers
- MV
98 papers · 4 as a fellow
- PR
94 papers · 2 as a fellow
- DB
92 papers
80 papers · 7 as a fellow
- JS
79 papers
75 papers
Grants
- 2006–2012
Molecular Basis Of Renal Cell Carcinoma Response to SU11428
National Cancer Institute · R01
Contact PI · $1.7M · Sloan-Kettering Inst Can Research
- 1999–2005
Clinical Trials and Mentoring in Oncology Research
National Cancer Institute · K24
Contact PI · $521.8K · Sloan-Kettering Inst Can Research
Clinical trials
- 2010–2014
Principal investigator · Completed · Phase 3
AVEO Pharmaceuticals, Inc.
- 2009–2013
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
Principal investigator · Completed · Phase 3
AVEO Pharmaceuticals, Inc.
- 2007–2010
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
- 2007–2008
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center